Published by Coherent Market Insights
Posted on September 30, 2021
Ioversol Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Ioversol Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/386
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Liebel-Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co., Mallinckrodt Pharmaceuticals, Ultraject, China Resources Pharmaceutical Co., HB Ocean, Changzhou Highassay Chemical Co., Ltd.
Ioversol, otherwise known as IOU peroxide, is used as a dialysis anticoagulant in hospitals for the treatment of dialysis patients and is used commercially for the treatment of toothache. It is an oxidizing agent for internal applications in the human body. The Ioversol chemical name is Isoflavones and contains seven carbon atoms with one hydrogen atom in common with many substances derived from plants (Isoflavones). Isoflavones are commonly found in fruits such as strawberry and lemon, and also in egg yolk and some vegetables, notably artichokes, parsley, beets, carrots, leek, and kidney beans. Ioversol (Iodine-Orient-containing Nutrient suspension) is generally used for the relief of inflammation and to treat infections, to prevent or reduce bleeding, as dialysis therapy and to increase blood flow and oxygenate blood
The growing prevalence of bone-related disorders is a prime factor driving the growth of the ioversol market. Increasing geriatric population around the globe which is increasing the prevalence of the various chronic disease. This has raised the demand for a various diagnostic tool such as X-ray which is another key factor fueling the growth of the market. According to the United Nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. The rise in spending on the healthcare sector by government for improving the patient care is further anticipated to propel the growth of the ioversol market.
North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of the bone-related disorder in the region which. In 2017, the number of Canadians affected by osteoporosis had increased to 2 million. By the year 2030, the number of hip fractures is expected to quadruple. Moreover, In Canadians of 40 years or older, 1.5 million (10%) reported having been diagnosed with osteoporosis. Thus the high prevalence of bone a related disorder is projected to foster the growth of the ioversol market.
Key Developments:
In December 2020, Guerbet (GBT), a global provider of medical imaging, announced that it received US Food and Drug Administration approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP) (Ioversol Injection) in the United States.
Buy This Premium Report Of Ioversol Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/386
In this study, the years considered to estimate the market size of Ioversol are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Ioversol Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Ioversol Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Ioversol Market Global Analysis 2021 | By Size, Valuable Share, Growth Overview, Regional Analysis, Key Opportunities appeared first on Gatorledger.
Ioversol Market (Forecast Period 2021-2028): The report provides a valuable source of insightful data for business strategists and competitive analysis of Ioversol Market. The study covers important knowledge that makes the analysis document a handy resource for managers, analysts, business consultants and different key individuals get ready-to-access and self-analyzed study in conjunction with graphs and tables to assist perceive market trends, drivers and market challenges.It also highlights the restraints and opportunities expected to influence the market’s growth during the said period. The study provides a holistic perspective on the market’s growth throughout the above mentioned forecast period in terms of revenue(in US$ Mn) and Volume (Thousand Units), across different geographies.
To Access the Sample Report Click Here: https://www.coherentmarketinsights.com/insight/request-sample/386
Note: *The Sample only consist of Table of Content (ToC), Research Framework of the actual report, and Research Methodology adopted for it.
Major Players In This Market Are: Liebel-Flarsheim Company LLC, Guerbet, Jiangsu Hengrui Medicine Co., Mallinckrodt Pharmaceuticals, Ultraject, China Resources Pharmaceutical Co., HB Ocean, Changzhou Highassay Chemical Co., Ltd.
Ioversol, otherwise known as IOU peroxide, is used as a dialysis anticoagulant in hospitals for the treatment of dialysis patients and is used commercially for the treatment of toothache. It is an oxidizing agent for internal applications in the human body. The Ioversol chemical name is Isoflavones and contains seven carbon atoms with one hydrogen atom in common with many substances derived from plants (Isoflavones). Isoflavones are commonly found in fruits such as strawberry and lemon, and also in egg yolk and some vegetables, notably artichokes, parsley, beets, carrots, leek, and kidney beans. Ioversol (Iodine-Orient-containing Nutrient suspension) is generally used for the relief of inflammation and to treat infections, to prevent or reduce bleeding, as dialysis therapy and to increase blood flow and oxygenate blood
The growing prevalence of bone-related disorders is a prime factor driving the growth of the ioversol market. Increasing geriatric population around the globe which is increasing the prevalence of the various chronic disease. This has raised the demand for a various diagnostic tool such as X-ray which is another key factor fueling the growth of the market. According to the United Nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. The rise in spending on the healthcare sector by government for improving the patient care is further anticipated to propel the growth of the ioversol market.
North America is projected to gain significant growth over the forecast period and this is attributed to the high prevalence of the bone-related disorder in the region which. In 2017, the number of Canadians affected by osteoporosis had increased to 2 million. By the year 2030, the number of hip fractures is expected to quadruple. Moreover, In Canadians of 40 years or older, 1.5 million (10%) reported having been diagnosed with osteoporosis. Thus the high prevalence of bone a related disorder is projected to foster the growth of the ioversol market.
Key Developments:
In December 2020, Guerbet (GBT), a global provider of medical imaging, announced that it received US Food and Drug Administration approval for the commercial sale of the Optiray® Imaging Bulk Package (IBP) (Ioversol Injection) in the United States.
Buy This Premium Report Of Ioversol Market Report 2021 With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/386
In this study, the years considered to estimate the market size of Ioversol are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2028
The next part also sheds light on the gap between supply and consumption. Apart from the mentioned information, growth rate of Ioversol Market in 2028 is also explained. Additionally, type wise and application wise consumption tables and figures of Ioversol Market are also given.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Ioversol Market Global Analysis 2021 | By Size, Valuable Share, Growth Overview, Regional Analysis, Key Opportunities appeared first on Gatorledger.
Explore more articles in the Research Reports category
